Avance Clinical Appoints Oncology SVP
The Australian-based CRO has named Wendy Hamon as the new Senior Vice President of its Oncology Centre of Excellence.
Updated on Oct. 21, 2026 in Cancer
Avance Clinical has appointed industry veteran Wendy Hamon to lead its Oncology Centre of Excellence. The move is intended to support the ongoing expansion of the organisation's clinical trial services.
Why it matters
The appointment aims to bolster Avance Clinical's capacity as it continues to manage complex oncology research. This leadership change aligns with the firm's goal to support emerging biotech companies in drug development.
Wendy Hamon brings over 28 years of pharmaceutical and contract research organisation experience to her new role. She joins a team that has delivered 260 oncology trials in the last five years.
The players
Wendy Hamon
Wendy Hamon is the newly appointed Senior Vice President of the Oncology Centre of Excellence at Avance Clinical.
Dr. George Peoples
Dr. George Peoples is the Executive Medical Director of the Oncology Centre of Excellence who has over three decades of experience in cancer vaccine development.
Avance Clinical
Avance Clinical is an Australian-headquartered contract research organisation that supports biotech firms with clinical trial management.
The details
The Oncology Centre of Excellence provides integrated support for clinical programmes from preclinical planning through Phase II trials. Wendy Hamon will work alongside Executive Medical Director Dr. George Peoples to oversee medical and operational leadership.
Timeline
21 October 2026: Avance Clinical announced the new appointment and its upcoming conference attendance.
23 October to 27 October 2026: The team will participate in the ESMO Congress 2026 in Madrid.
The Big Picture
The appointment positions Avance Clinical to showcase its research capabilities during the ESMO Congress. This strategic move aligns the firm's leadership with the international standards and clinical trial developments discussed at the event.
The expansion of the Oncology Centre of Excellence may increase the availability of clinical trials for patients with diverse cancer diagnoses. By partnering with biotech firms, the organisation accelerates the development of new immunotherapy and vaccine treatments.
The takeaway
The appointment highlights the continued investment in specialised leadership for drug trial management. This ensures that emerging biotechs have the necessary operational support to advance complex oncology programmes to the next clinical phase.
What happens next
Avance Clinical representatives will attend the ESMO Congress 2026, which is scheduled to take place from 23 October to 27 October 2026.
Further reading
For more information on the evolving landscape of drug development, visit the Cancer section.
